Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists

Verfasser / Beitragende:
[Hidde Braam, Djamila Boerma, Marinus Wiezer, Bert van Ramshorst]
Ort, Verlag, Jahr:
2015
Enthalten in:
International Journal of Clinical Oncology, 20/5(2015-10-01), 928-934
Format:
Artikel (online)
ID: 605491518
LEADER caa a22 4500
001 605491518
003 CHVBK
005 20210128100510.0
007 cr unu---uuuuu
008 210128e20151001xx s 000 0 eng
024 7 0 |a 10.1007/s10147-015-0816-5  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s10147-015-0816-5 
245 0 0 |a Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists  |h [Elektronische Daten]  |c [Hidde Braam, Djamila Boerma, Marinus Wiezer, Bert van Ramshorst] 
520 3 |a Background: Controversy still exists regarding the position of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis of colorectal carcinoma. The goal of the current study was to evaluate the opinions about this treatment among Dutch oncologic surgeons and medical oncologists. Methods: An online survey was sent to all known Dutch oncologic surgeons (n=459) and medical oncologists (n=363) representing the respective departments of 84 hospitals. A comparison was made between surgeons and oncologists. Results: 185 eligible responses were received from 71 hospitals, resulting in a response rate of 23% for individuals and a response rate of 85% for hospitals. Overall, 65% of respondents regarded CRS+HIPEC as effective with sufficient evidence, 29% responded that CRS+HIPEC is probably effective without sufficient evidence, and 7% of respondents regards HIPEC as probably ineffective. Medical oncologists were less convinced of the effectiveness of CRS+HIPEC than surgeons (P=0.006). Of all the respondents, 68% indicated that they regard CRS+HIPEC as a standard treatment for patients with peritoneal dissemination of colorectal carcinoma (77 % of surgeons vs 54% of oncologists, P=0.001). Additionally, 68% of respondents regard CRS+HIPEC as potentially curative (77 % of surgeons vs 54% of oncologists, P=0.001). Conclusions: Approximately 30% of physicians who treat colorectal carcinoma do not regard CRS+HIPEC as standard care. Surgeons appear to be significantly more in favor of this treatment than medical oncologists. This study shows that efforts should be made to improve knowledge and increase acceptance of CRS and HIPEC in colorectal cancer treatment among medical oncologists and surgeons. 
540 |a Japan Society of Clinical Oncology, 2015 
690 7 |a Colorectal neoplasms  |2 nationallicence 
690 7 |a Peritoneal neoplasms  |2 nationallicence 
690 7 |a Questionnaires  |2 nationallicence 
690 7 |a Medical oncology  |2 nationallicence 
690 7 |a Surgery  |2 nationallicence 
690 7 |a Chemotherapy  |2 nationallicence 
700 1 |a Braam  |D Hidde  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
700 1 |a Boerma  |D Djamila  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
700 1 |a Wiezer  |D Marinus  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
700 1 |a van Ramshorst  |D Bert  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
773 0 |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/5(2015-10-01), 928-934  |x 1341-9625  |q 20:5<928  |1 2015  |2 20  |o 10147 
856 4 0 |u https://doi.org/10.1007/s10147-015-0816-5  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s10147-015-0816-5  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Braam  |D Hidde  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Boerma  |D Djamila  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Wiezer  |D Marinus  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a van Ramshorst  |D Bert  |u Department of Surgery, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t International Journal of Clinical Oncology  |d Springer Japan  |g 20/5(2015-10-01), 928-934  |x 1341-9625  |q 20:5<928  |1 2015  |2 20  |o 10147